- WKN: 703712
- ISIN: DE0007037129
- Land: Deutschland
Nachricht vom 09.09.2021 | 09:59
RWE Aktiengesellschaft: Release of a capital market information
/ Share Buyback
Notification in accordance with Article 5, para. 1 lit. b) and para. 3 of Regulation (EU) 596/2014 and Article 2, para. 3 of Delegated Regulation (EU) 2016/1052
On 22 December 2020 RWE Aktiengesellschaft announced share buyback programs of RWE Supply & Trading GmbH UK Branch, RWE Generation UK plc and RWE Technology UK Limited pursuant to Art. 5 para. 1 lit. a) of the Regulation (EU) no. 596/2014 in connection with Art. 2 para. 1 of the Delegated Regulation (EU) 2016/1052 of the Commission.
In September 2021 Computershare Trustees Limited as the independent Trustee acquired on behalf of RWE Supply & Trading GmbH UK Branch, RWE Generation UK plc and RWE Technology UK Limited a total of 475 shares of RWE Aktiengesellschaft under the currently conducted share buyback programs. The average purchase price paid on the stock market was GBP 29.305083. The company bought back shares for a total price of GBP 13,919.914 (excluding ancillary costs).
The acquisition of shares of RWE Aktiengesellschaft was exclusively executed in the stock market at Frankfurt Stock Exchange (XFRA).
Detailed information on the transactions pursuant to Art. 2 para. 3 of the Delegated Regulation (EU) 2016/1052 of the Commission is published in the 'Investor Relations' section on RWE Aktiengesellschaft's website (http://www.rwe.com/).
|RWE Platz 1|
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
29. November 06:35 DAX nach Kursrutsch im Plus erwartet, Omikron-Variante im Fokus, ...
29. November 06:39 Commerzbank: Rebound nach Absturz?
29. November 06:49 Varta-Aktie: 76 oder 140 Euro – welcher Experte behält recht?
29. November 06:50 Vulcan Energy: "Wichtiges Signal für den europäischen Lithium-Markt"
29. November 07:00 Gerd Weger: "Der Kryptomarkt verspricht weiter Renditen von 100 ...
Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten
26. November 2021